一分钟看懂
这是一项关于急性髓系白血病的II 期研究，登记的药物或干预包括Biospecimen Collection；Bone Marrow Aspiration；Bone Marrow Biopsy；Decitabine and Cedazuridine；Enasidenib；Venetoclax，当前状态为招募中。登记地点显示中国Tucson、Little Rock、Berkeley、San Francisco等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Bone Marrow Aspiration；Bone Marrow Biopsy；Decitabine and Cedazuridine；Enasidenib；Venetoclax · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Banner University Medical Center - Tucson · Tucson
- University of Arizona Cancer Center-North Campus · Tucson
- University of Arkansas for Medical Sciences · Little Rock
- Alta Bates Summit Medical Center-Herrick Campus · Berkeley
- UCSF Medical Center-Parnassus · San Francisco
- Mills Health Center · San Mateo
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital · Hollywood
- Miami Cancer Institute · Miami
- Memorial Hospital West · Pembroke Pines
- Augusta University Medical Center · Augusta
- Saint Luke's Cancer Institute - Boise · Boise
- Kootenai Health - Coeur d'Alene · Coeur d'Alene
- Saint Luke's Cancer Institute - Fruitland · Fruitland
- Saint Luke's Cancer Institute - Meridian · Meridian
- Saint Alphonsus Cancer Care Center-Nampa · Nampa
- Saint Luke's Cancer Institute - Nampa · Nampa
- Kootenai Clinic Cancer Services - Post Falls · Post Falls
- Kootenai Clinic Cancer Services - Sandpoint · Sandpoint
- Northwestern University · Chicago
- University of Illinois · Chicago
- University of Chicago Comprehensive Cancer Center · Chicago
- Northwestern Medicine Cancer Center Kishwaukee · DeKalb
- NorthShore University HealthSystem-Evanston Hospital · Evanston
- Northwestern Medicine Cancer Center Delnor · Geneva
- NorthShore University HealthSystem-Glenbrook Hospital · Glenview
- Northwestern Medicine Glenview Outpatient Center · Glenview
- Northwestern Medicine Grayslake Outpatient Center · Grayslake
- NorthShore University HealthSystem-Highland Park Hospital · Highland Park
- Edward Hines Jr VA Hospital · Hines
- Northwestern Medicine Lake Forest Hospital · Lake Forest
公开的入选条件
- * Participants must have been registered to the MYELOMATCH Master Screening and Reassessment Protocol prior to consenting to this study. Participants must have disease with a detectable IDH2 mutation based on central testing through the MYELOMATCH and be assig
- Note: Pre-enrollment/diagnosis labs must have already been performed under MYELOMATCH
- * Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) defined by having ≥ 20% blasts in the bone marrow and/or peripheral blood, or with an AML defining genetic abnormality as described by the World Health Organization (WHO) classifi
- * Participants must not be receiving or planning to receive any other investigational agents while on protocol therapy
- * Participants must not have received prior therapy for AML, myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) with the exception of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, colony-stimulating f
- Note: White blood cell (WBC) must be \< 25 x 10\^9/L prior to start of treatment. Hydroxyurea, leukapheresis, and cytarabine ≤ 1g/m\^2 are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped prior to
- * Participants must be ≥ 60 years old; OR must be ≥ 18 years old and considered not eligible for cytarabine-based induction therapy
- * Participants must have Zubrod Performance Status of 0-3 as determined by a history and physical (H\&P) exam completed within 14 days prior to registration
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06672146；登记信息更新于 2026-09-17。